A phase IV, non-randomised, study of Modrenal (Trilostane) in post-menopausal women with advanced, oestrogen receptor positive breast cancer for whom prior endocrine therapies have failed, one of which was an aromatase inhibitor

Trial Profile

A phase IV, non-randomised, study of Modrenal (Trilostane) in post-menopausal women with advanced, oestrogen receptor positive breast cancer for whom prior endocrine therapies have failed, one of which was an aromatase inhibitor

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 May 2006

At a glance

  • Drugs Trilostane (Primary)
  • Indications Advanced breast cancer; Menopause
  • Focus Therapeutic Use
  • Sponsors Bioenvision
  • Most Recent Events

    • 19 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top